{
  "success": true,
  "pagesUsed": [
    2,
    3,
    4,
    5,
    10,
    11,
    12,
    13,
    25,
    26,
    27,
    28
  ],
  "modelUsed": "gemini-3-flash-preview",
  "objectivesEndpoints": {
    "objectives": [
      {
        "id": "obj_1",
        "name": "Primary Objective",
        "text": "The trial will continue until the required number of adjudicated primary endpoint events have occurred to be able to comply with the objective of the trial.",
        "level": {
          "code": "C85826",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Primary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_1"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_2",
        "name": "Key Secondary Objectives",
        "text": "To evaluate key secondary endpoints which are part of the testing strategy",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_2",
          "ep_3"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_3",
        "name": "Other Secondary Objectives",
        "text": "To evaluate other secondary endpoints",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_4",
          "ep_5",
          "ep_6",
          "ep_7",
          "ep_8",
          "ep_9",
          "ep_10"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_4",
        "name": "Safety Objective",
        "text": "Safety will be evaluated descriptively on the treated set.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_11",
          "ep_12",
          "ep_13",
          "ep_14",
          "ep_15",
          "ep_16",
          "ep_17"
        ],
        "instanceType": "Objective"
      }
    ],
    "endpoints": [
      {
        "id": "ep_1",
        "name": "Primary Endpoint",
        "text": "The composite primary endpoint for this trial is the time to first event of adjudicated CV death or adjudicated HHF in patients with HFrEF.",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_2",
        "name": "Key Secondary Endpoint 1",
        "text": "Occurrence of adjudicated HHF (first and recurrent)",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_3",
        "name": "Key Secondary Endpoint 2",
        "text": "eGFR (CKD-EPI)cr slope of change from baseline",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_4",
        "name": "Other Secondary Endpoint 1",
        "text": "Time to first occurrence of chronic dialysis or renal transplant or sustained reduction of ≥40% eGFR (CKD-EPI)cr or sustained eGFR (CKD-EPI)cr <15 mL/min/1.73 m2 for patients with baseline eGFR ≥30 mL/min/1.73 m2 or sustained eGFR (CKD-EPI)cr <10 mL/min/1.73 m2 for patients with baseline eGFR <30 mL/min/1.73 m2",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_5",
        "name": "Other Secondary Endpoint 2",
        "text": "Time to first adjudicated HHF",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_6",
        "name": "Other Secondary Endpoint 3",
        "text": "Time to adjudicated CV death",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_7",
        "name": "Other Secondary Endpoint 4",
        "text": "Time to all-cause mortality",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_8",
        "name": "Other Secondary Endpoint 5",
        "text": "Time to onset of diabetes mellitus (DM) in patients with pre-DM",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_9",
        "name": "Other Secondary Endpoint 6",
        "text": "Change from baseline in clinical summary score (HF symptoms and physical limitations domains) of the KCCQ at week 52",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "QualityOfLife"
      },
      {
        "id": "ep_10",
        "name": "Other Secondary Endpoint 7",
        "text": "Occurrence of all-cause hospitalisation (first and recurrent)",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_11",
        "name": "Safety Criterion 1",
        "text": "Adverse events (AE)",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_12",
        "name": "Safety Criterion 2",
        "text": "AE of special interest (AESI)",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_13",
        "name": "Safety Criterion 3",
        "text": "Incidence and intensity of AE including serious AE (SAE)",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_14",
        "name": "Safety Criterion 4",
        "text": "Withdrawal from trial medication due to AE",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_15",
        "name": "Safety Criterion 5",
        "text": "Clinically relevant new finding or worsening of existing condition on physical examination",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_16",
        "name": "Safety Criterion 6",
        "text": "Clinically relevant changes in laboratory measurements from baseline",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_17",
        "name": "Safety Criterion 7",
        "text": "Assessment of vital status",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      }
    ],
    "estimands": [
      {
        "id": "est_1",
        "name": "Primary Efficacy Estimand",
        "populationSummary": "Adult patients with chronic heart failure (NYHA II-IV), LVEF ≤ 40%, and elevated NT-proBNP (ITT population) Summary measure: Hazard ratio (from Cox proportional hazards regression model).",
        "analysisPopulationId": "est_1_pop",
        "variableOfInterestId": "ep_1",
        "interventionIds": [
          "est_1_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_1",
            "name": "Treatment discontinuation",
            "text": "Premature discontinuation of trial medication",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_2",
            "name": "Death",
            "text": "Death due to non-cardiovascular causes",
            "strategy": "Composite",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Empagliflozin 10 mg q.d. vs Placebo",
        "analysisPopulation": "Adult patients with chronic heart failure (NYHA II-IV), LVEF ≤ 40%, and elevated NT-proBNP (ITT population)",
        "variableOfInterest": "Time to first event of adjudicated CV death or adjudicated HHF",
        "summaryMeasure": "Hazard ratio (from Cox proportional hazards regression model)"
      },
      {
        "id": "est_2",
        "name": "Key Secondary Estimand 1",
        "populationSummary": "Adult patients with chronic heart failure (NYHA II-IV), LVEF ≤ 40%, and elevated NT-proBNP (ITT population) Summary measure: Rate ratio.",
        "analysisPopulationId": "est_2_pop",
        "variableOfInterestId": "ep_2",
        "interventionIds": [
          "est_2_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_1",
            "name": "Treatment discontinuation",
            "text": "Premature discontinuation of trial medication",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_3",
            "name": "Death",
            "text": "Death prior to HHF event",
            "strategy": "Composite",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Empagliflozin 10 mg q.d. vs Placebo",
        "analysisPopulation": "Adult patients with chronic heart failure (NYHA II-IV), LVEF ≤ 40%, and elevated NT-proBNP (ITT population)",
        "variableOfInterest": "Occurrence of adjudicated HHF (first and recurrent)",
        "summaryMeasure": "Rate ratio"
      },
      {
        "id": "est_3",
        "name": "Key Secondary Estimand 2",
        "populationSummary": "Adult patients with chronic heart failure (NYHA II-IV), LVEF ≤ 40%, and elevated NT-proBNP (ITT population) Summary measure: Difference in slopes.",
        "analysisPopulationId": "est_3_pop",
        "variableOfInterestId": "ep_3",
        "interventionIds": [
          "est_3_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_1",
            "name": "Treatment discontinuation",
            "text": "Premature discontinuation of trial medication",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_4",
            "name": "Death",
            "text": "Death prior to completion of follow-up",
            "strategy": "While on Treatment",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Empagliflozin 10 mg q.d. vs Placebo",
        "analysisPopulation": "Adult patients with chronic heart failure (NYHA II-IV), LVEF ≤ 40%, and elevated NT-proBNP (ITT population)",
        "variableOfInterest": "eGFR (CKD-EPI)cr slope of change from baseline",
        "summaryMeasure": "Difference in slopes"
      }
    ],
    "summary": {
      "primaryObjectives": 1,
      "secondaryObjectives": 3,
      "exploratoryObjectives": 0,
      "totalEndpoints": 17,
      "totalEstimands": 3
    }
  },
  "rawResponse": {
    "objectives": [
      {
        "id": "obj_1",
        "name": "Primary Objective",
        "text": "The trial will continue until the required number of adjudicated primary endpoint events have occurred to be able to comply with the objective of the trial.",
        "level": {
          "code": "C85826",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Primary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_1"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_2",
        "name": "Key Secondary Objectives",
        "text": "To evaluate key secondary endpoints which are part of the testing strategy",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_2",
          "ep_3"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_3",
        "name": "Other Secondary Objectives",
        "text": "To evaluate other secondary endpoints",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_4",
          "ep_5",
          "ep_6",
          "ep_7",
          "ep_8",
          "ep_9",
          "ep_10"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_4",
        "name": "Safety Objective",
        "text": "Safety will be evaluated descriptively on the treated set.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_11",
          "ep_12",
          "ep_13",
          "ep_14",
          "ep_15",
          "ep_16",
          "ep_17"
        ],
        "instanceType": "Objective"
      }
    ],
    "endpoints": [
      {
        "id": "ep_1",
        "name": "Primary Endpoint",
        "text": "The composite primary endpoint for this trial is the time to first event of adjudicated CV death or adjudicated HHF in patients with HFrEF.",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_2",
        "name": "Key Secondary Endpoint 1",
        "text": "Occurrence of adjudicated HHF (first and recurrent)",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_3",
        "name": "Key Secondary Endpoint 2",
        "text": "eGFR (CKD-EPI)cr slope of change from baseline",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_4",
        "name": "Other Secondary Endpoint 1",
        "text": "Time to first occurrence of chronic dialysis or renal transplant or sustained reduction of ≥40% eGFR (CKD-EPI)cr or sustained eGFR (CKD-EPI)cr <15 mL/min/1.73 m2 for patients with baseline eGFR ≥30 mL/min/1.73 m2 or sustained eGFR (CKD-EPI)cr <10 mL/min/1.73 m2 for patients with baseline eGFR <30 mL/min/1.73 m2",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_5",
        "name": "Other Secondary Endpoint 2",
        "text": "Time to first adjudicated HHF",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_6",
        "name": "Other Secondary Endpoint 3",
        "text": "Time to adjudicated CV death",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_7",
        "name": "Other Secondary Endpoint 4",
        "text": "Time to all-cause mortality",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_8",
        "name": "Other Secondary Endpoint 5",
        "text": "Time to onset of diabetes mellitus (DM) in patients with pre-DM",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_9",
        "name": "Other Secondary Endpoint 6",
        "text": "Change from baseline in clinical summary score (HF symptoms and physical limitations domains) of the KCCQ at week 52",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "QualityOfLife"
      },
      {
        "id": "ep_10",
        "name": "Other Secondary Endpoint 7",
        "text": "Occurrence of all-cause hospitalisation (first and recurrent)",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_11",
        "name": "Safety Criterion 1",
        "text": "Adverse events (AE)",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_12",
        "name": "Safety Criterion 2",
        "text": "AE of special interest (AESI)",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_13",
        "name": "Safety Criterion 3",
        "text": "Incidence and intensity of AE including serious AE (SAE)",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_14",
        "name": "Safety Criterion 4",
        "text": "Withdrawal from trial medication due to AE",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_15",
        "name": "Safety Criterion 5",
        "text": "Clinically relevant new finding or worsening of existing condition on physical examination",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_16",
        "name": "Safety Criterion 6",
        "text": "Clinically relevant changes in laboratory measurements from baseline",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_17",
        "name": "Safety Criterion 7",
        "text": "Assessment of vital status",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      }
    ],
    "estimands": [
      {
        "id": "est_1",
        "name": "Primary Efficacy Estimand",
        "populationSummary": "Adult patients with chronic heart failure (NYHA II-IV), LVEF ≤ 40%, and elevated NT-proBNP (ITT population) Summary measure: Hazard ratio (from Cox proportional hazards regression model).",
        "analysisPopulationId": "est_1_pop",
        "variableOfInterestId": "ep_1",
        "interventionIds": [
          "est_1_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_1",
            "name": "Treatment discontinuation",
            "text": "Premature discontinuation of trial medication",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_2",
            "name": "Death",
            "text": "Death due to non-cardiovascular causes",
            "strategy": "Composite",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Empagliflozin 10 mg q.d. vs Placebo",
        "analysisPopulation": "Adult patients with chronic heart failure (NYHA II-IV), LVEF ≤ 40%, and elevated NT-proBNP (ITT population)",
        "variableOfInterest": "Time to first event of adjudicated CV death or adjudicated HHF",
        "summaryMeasure": "Hazard ratio (from Cox proportional hazards regression model)"
      },
      {
        "id": "est_2",
        "name": "Key Secondary Estimand 1",
        "populationSummary": "Adult patients with chronic heart failure (NYHA II-IV), LVEF ≤ 40%, and elevated NT-proBNP (ITT population) Summary measure: Rate ratio.",
        "analysisPopulationId": "est_2_pop",
        "variableOfInterestId": "ep_2",
        "interventionIds": [
          "est_2_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_1",
            "name": "Treatment discontinuation",
            "text": "Premature discontinuation of trial medication",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_3",
            "name": "Death",
            "text": "Death prior to HHF event",
            "strategy": "Composite",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Empagliflozin 10 mg q.d. vs Placebo",
        "analysisPopulation": "Adult patients with chronic heart failure (NYHA II-IV), LVEF ≤ 40%, and elevated NT-proBNP (ITT population)",
        "variableOfInterest": "Occurrence of adjudicated HHF (first and recurrent)",
        "summaryMeasure": "Rate ratio"
      },
      {
        "id": "est_3",
        "name": "Key Secondary Estimand 2",
        "populationSummary": "Adult patients with chronic heart failure (NYHA II-IV), LVEF ≤ 40%, and elevated NT-proBNP (ITT population) Summary measure: Difference in slopes.",
        "analysisPopulationId": "est_3_pop",
        "variableOfInterestId": "ep_3",
        "interventionIds": [
          "est_3_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_1",
            "name": "Treatment discontinuation",
            "text": "Premature discontinuation of trial medication",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_4",
            "name": "Death",
            "text": "Death prior to completion of follow-up",
            "strategy": "While on Treatment",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Empagliflozin 10 mg q.d. vs Placebo",
        "analysisPopulation": "Adult patients with chronic heart failure (NYHA II-IV), LVEF ≤ 40%, and elevated NT-proBNP (ITT population)",
        "variableOfInterest": "eGFR (CKD-EPI)cr slope of change from baseline",
        "summaryMeasure": "Difference in slopes"
      }
    ]
  }
}